{"generic":"Basiliximab","drugs":["Basiliximab","Simulect"],"mono":{"0":{"id":"jtiqs0","title":"Generic Names","mono":"Basiliximab"},"1":{"id":"jtiqs1","title":"Dosing and Indications","sub":{"0":{"id":"jtiqs1b4","title":"Adult Dosing","mono":"<ul><li><b>Liver transplant rejection; Prophylaxis:<\/b> 20 mg IV within 2 hr before transplant surgery; then another 20 mg IV dose day 4 post-op<\/li><li><b>Renal transplant rejection, in combination with cyclosporine and corticosteroids; Prophylaxis:<\/b> IV; 20 mg IV within 2 hr before transplant surgery; then another 20 mg IV dose day 4 post-op<\/li><\/ul>"},"1":{"id":"jtiqs1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Renal transplant rejection, in combination with cyclosporine and corticosteroids; Prophylaxis:<\/b> IV; (weight less than 35 kg) 2 doses of 10 mg each; first dose within 2 hr prior to transplant, second dose 4 days after transplant; withhold second dose if complications occur<\/li><li><b>Renal transplant rejection, in combination with cyclosporine and corticosteroids; Prophylaxis:<\/b> IV; (weight 35 kg or more) 2 doses of 20 mg each; first dose within 2 hr prior to transplant, second dose 4 days after transplant; withhold second dose if complications occur<\/li><\/ul>"},"3":{"id":"jtiqs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Renal transplant rejection, in combination with cyclosporine and corticosteroids; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Graft versus host disease<\/li><li>Liver transplant rejection; Prophylaxis<\/li><\/ul>"}}},"2":{"id":"jtiqs2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe basiliximab and they should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.<br\/>"},"3":{"id":"jtiqs3","title":"Contraindications\/Warnings","sub":[{"id":"jtiqs3b9","title":"Contraindications","mono":"hypersensitivity to basiliximab products<br\/>"},{"id":"jtiqs3b10","title":"Precautions","mono":"<ul><li>severe acute hypersensitivity reactions have occurred with initial exposure and\/or following re-exposure<\/li><li>history of untoward events related to use of basiliximab, daclizumab, or other monoclonal antibodies<\/li><li>basiliximab is indicated only in conjunction with other immunosuppressants (cyclosporine corticosteroids); all relative\/absolute contraindications for these latter agents also apply whenever basiliximab is administered<\/li><li>elderly patients<\/li><\/ul>"},{"id":"jtiqs3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jtiqs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jtiqs4","title":"Drug Interactions","sub":{"1":{"id":"jtiqs4b14","title":"Major","mono":"<ul><li>Echinacea (theoretical)<\/li><li>Tacrolimus (probable)<\/li><\/ul>"}}},"5":{"id":"jtiqs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain, Vomiting<\/li><li><b>Neurologic:<\/b>Asthenia, Dizziness, Insomnia<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Edema, Hypertension<\/li><li><b>Hematologic:<\/b>Anemia<\/li><li><b>Immunologic:<\/b>Allergic reaction, acute<\/li><li><b>Renal:<\/b>Dysuria<\/li><li><b>Respiratory:<\/b>Candidiasis (frequent), Cough (frequent), Dyspnea (frequent)<\/li><li><b>Other:<\/b>Cytomegalovirus infection, Fever (frequent)<\/li><\/ul>"},"6":{"id":"jtiqs6","title":"Drug Name Info","sub":{"0":{"id":"jtiqs6b17","title":"US Trade Names","mono":"Simulect<br\/>"},"2":{"id":"jtiqs6b19","title":"Class","mono":"<ul><li>Immune Suppressant<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"jtiqs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jtiqs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jtiqs7","title":"Mechanism Of Action","mono":"Systemic: Basiliximab is an interleukin-2 (IL-2) receptor antagonist that binds to the alpha subunit of the IL-2 receptor complex and inhibits IL-2 binding . By inhibiting IL-2 binding, IL-2-mediated activation of lymphocytes is prevented, and the response of the immune system to antigens is impaired .<br\/>"},"8":{"id":"jtiqs8","title":"Pharmacokinetics","sub":{"1":{"id":"jtiqs8b24","title":"Distribution","mono":"Systemic: Vd: 8.6  plus or minus  4.1 L Adults; 10.1  plus or minus  7.6 L  Adolescents; 5.2  plus or minus  2.8 L  Children <br\/>"},"4":{"id":"jtiqs8b27","title":"Elimination Half Life","mono":"Systemic: 7.2  plus or minus  3.2 d Adults; 7.2  plus or minus  3.6 d  Adolescents; 11.5  plus or minus  6.3 d Children<br\/>"}}},"9":{"id":"jtiqs9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>for central or peripheral intravenous use only<\/li><li>to reconstitute, add 2.5 or 5 mL Sterile Water for Injection to the 10 mg and 20 mg vials, respectively<\/li><li>use solution within 4 h after reconstitution at room temp or 24 h under refrigeration<\/li><li>(bolus) reconstituted solution is isotonic and may be given as an IV bolus injection<\/li><li>(infusion) solution may be further diluted to 25-50 mL NS or D5W and infused over 20-30 min<\/li><\/ul>"},"10":{"id":"jtiqs10","title":"Monitoring","mono":"<ul><li>signs\/symptoms of rejection<\/li><li>CBC<\/li><li>renal function<\/li><li>signs\/symptoms of infection<\/li><li>acute hypersensitivity reactions (including anaphylaxis)<\/li><\/ul>"},"11":{"id":"jtiqs11","title":"How Supplied","mono":"<b>Simulect<\/b><br\/>Intravenous Powder for Solution: 10 MG, 20 MG<br\/>"},"13":{"id":"jtiqs13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause abdominal pain, vomiting, asthenia, dizziness, insomnia, edema, anemia, or dysuria.<\/li><li>Drug may frequently cause candidiasis, cough, dyspnea, or fever.<\/li><li>Instruct patient to report signs\/symptoms of infection or organ rejection.<\/li><\/ul>"}}}